Chemotherapy before surgery for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer or cancer where the stomach meets the esophagus (Siewert type 2 or 3) that has spread into nearby tissue but not to distant organs.
- You are well enough to be active and care for yourself (ECOG score 0 or 1).
- Your cancer is confirmed by a biopsy (tissue sample).
- You have not had another cancer in the last 5 years that required radical treatment.
- You are able to receive chemotherapy without serious health risks.
- You agree to take part in the study and follow the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial compares giving chemotherapy before surgery versus going straight to surgery in older adults with stage III stomach (or where the esophagus meets the stomach) cancer. It’s meant to see which approach works better to control the cancer and improve outcomes.
This trial tests a combination of four chemotherapy drugs (irinotecan liposome, 5-FU + leucovorin, oxaliplatin, and Karelizumab) given before surgery to shrink stomach cancer. The goal is to see if this combination makes the cancer easier to remove and improves outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.